Malken Bayrakdarian active positions
Companies | Position | Start | End |
---|---|---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Director/Board Member | - | - |
Career history of Malken Bayrakdarian
Statistics
International
Canada | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Health Technology |
- Stock Market
- Insiders
- Malken Bayrakdarian
- Experience